BMS’s Opdivo and Yervoy colorectal cancer trials show promising results
BMS presented this data supporting the use of immune checkpoint inhibitors (ICIs) in combination in patients with newly diagnosed advanced colorectal cancer subtypes at the ASCO Gastrointestinal Cancer Symposium. Credit: Tada Images / Shutterstock. On January 22, BMS announced encouraging findings from the CheckMate -8HW clinical trial, showing that the combination of Opdivo (nivolumab) and […]
BMS’ Opdivo regimen shows promise in colorectal cancer clinical trials
BMS’ Opdivo plus Yervoy significantly improved progression-free survival in patients with MSI-H/dMMR metastatic colorectal cancer. Credit: Bristol-Myers Squibb Company. bristol myers squib (BMS) is a Phase III CheckMate-8HW clinical trial combining Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment option for microsatellite-high instability (MSI-H) or mismatch repair deficiency (dMMR). reported promising data. Metastatic colorectal […]
BMS Demonstrates Rationale for Opdivo and Yervoy Combination Therapy in First-Line Colorectal Cancer
Photo: California BMS Building Exterior/iStock, hapa bapa Bristol-Myers Squibb on Thursday announced data from the Phase 3 CheckMate-8HW study demonstrating first-line potential for Opdivo (nivolumab) and Yervoy (ipilimumab) combination therapy in metastatic colorectal cancer. . BMS did not provide specific data in Thursday’s announcement, but the company said the combination therapy showed “statistically significant results” […]
BMS’s Opdivo meets co-primary endpoint in colorectal cancer trial
Despite Opdivo’s success in combination trials, Bristol-Myers Squibb faces challenges as Opdivo’s European and U.S. patents expire in 2026 and 2028, respectively, threatening sales growth. There is. Credit: Dennis Diatel, via ShutterStock. Bristol-Myers Squibb (BMS) announced that its Phase III CheckMate-8HW study of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of metastatic […]